To study the safety and feasibility of giving intralesional GRm13Z40-2, an allogeneic CD8(cytotoxic T cell line genetically modified to express the IL-13 zetakine chimeric immunoreceptor and the Hy/TK selection/suicide fusion protein and found to be resistant to corticosteroids together with aldesleukin in treating patients with malignant glioma. Here, KDM5D is linked to malignant glioma.